Navigation Links
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Date:3/31/2008

hese cases, HPV testing can help determine appropriate medical management. The other arm enrolls women over age 30 whose Pap results are normal. This arm will assess the ability of the APTIMA HPV test to identify women who are at greater risk for cervical cancer.

Gen-Probe expects to enroll approximately 7,000 women in the study. Actual enrollment, however, may vary based on the prevalence of cervical disease among women in the trial. The trial enrollment and testing are expected to take approximately two years.

The APTIMA HPV assay is designed to run on Gen-Probe's fully automated, high-throughput TIGRIS(R) instrument system, and on the Company's current and future medium-throughput instrument platforms.

Separately, Gen-Probe remains on track to introduce its APTIMA HPV assay as a CE-marked product in Europe in the second half of 2008.

About HPV and Cervical Cancer

HPV is a group of viruses with more than 100 types, 14 of which have been categorized as high risk for the development of cervical cancer. While most women will be infected with HPV at some point in their lives, the majority of these infections are transient and resolve without any clinical symptoms or consequences. However, a small number of HPV infections progress and result in disease ranging from genital warts to cervical cancer. Since most HPV infections do not result in cancer, there is a need for a more specific test to identify women at greater risk of developing that disease.

The most common test used for cervical cancer screening in the United States is the Pap test. Since the mid-1950s, screening with the Pap test has dramatically reduced the number of deaths from cervical cancer. Even so, the American Cancer Society estimates that there were more than 11,000 new cases of invasive cervical cancer in 2007, as well as nearly 4,000 deaths from the disease.

Despite the success of Pap testing in reducing mortality from cervical cancer in the United S
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ... recently closed a bridge loan financing (the "2009 ... Purchase Agreement (the "Agreement") with Firebird Global Master ... Company sold a convertible promissory note, due June ... US$1,400,000, and issued a warrant to purchase an ...
(Date:12/16/2009)... 16 International, well-known,scientific experts ... GFT505 (80 mg/day),data presented as "extremely ... scientists and clinicians critically reviewed these ... of generic lipid-modifying,treatments, fenofibrate and bezafibrate, ... observed in patients with metabolic syndrome,and ...
(Date:12/16/2009)... Boston Scientific Corporation (NYSE: BSX ... has elected Nelda Connors as a Director. ... and Metal Products division of Tyco International. Previously, ... several positions in operations and general management. Prior ... of executive and management capacities with Ford, Chrysler and ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 1Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 2Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 3Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 4Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 5IgeaCare Solutions Inc Emerges Under New Leadership and Funding 11022 1IgeaCare Solutions Inc Emerges Under New Leadership and Funding 11022 2New approach to sickle cell disease shows promise in mice 62780 1New approach to sickle cell disease shows promise in mice 62780 2
... -, BRIDGEWATER, N.J., Sept. 18 Results ... study showed that 84 percent of,treatment-naive HIV-1 infected ... mg (two 400 mg tablets) with 100 mg ... reached an undetectable viral load (<50 copies/mL) at ...
... FOLD ) today announced that it plans to ... HCl) for Pompe Disease at the,American Society of Human ... CA. This plan was announced by John Crowley, President ... & Medtech 2007 Conference in London, United Kingdom. ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease 2
(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...
(Date:12/16/2009)... 16 For wounded U.S. servicemen ... in Washington, D.C., the holidays can be a particularly ... travel home rely more than ever on the healing ... week, calling home just got easier for Walter Reed ... cards, which will provide hundreds of minutes of holiday ...
(Date:12/16/2009)... -- HealthSciences Institute will sponsor a new ... and organizations who serve individuals at risk ... employer, health plan, medical home and other ... free, noncommercial webinars on topics, solutions and ... and care improvement. Each webinar will include ...
(Date:12/16/2009)... a role in reducing inflammation in the lungs , , ... that plays a role in inflammation seems to protect ... adults who smoke. , Researchers also found that adult ... a lower risk of developing chronic obstructive pulmonary disease ... , "The gene seems to be protective of the ...
(Date:12/16/2009)... GAINESVILLE, Fla. University of Florida researchers at work ... the first to predict the spread of the disease ... than 21 million calls to determine how often residents ... region composed of two islands off the coast of ... in recent years. Its government commissioned the study as ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3
... - CRH Medical Corporation,(CRM:TSX-V) announced today that it ... Chicago. The new Clinic will be located west ... CRH,s overall,patient appointment capacity and expands accessibility to ... the Chicago expansion, Edward Wright CEO of CRH ...
... Oct. 10 Major financial implications are,at stake ... record,the health conditions of patients that are present ... Centers for Medicare and Medicaid,Services (CMS). CMS ... (DRG),assignment, including new methods for identifying patients who ...
... 10 Abbott has been named to,Hispanic Business ... Abbott was recognized as one of the magazine,s ... hiring, promotion, marketing,philanthropy and supplier diversity. "As ... of our,people to provide different ideas, perspectives and ...
... Web Cast Set for 11:00 a.m. EDT, POWAY, ... a leading provider of diagnostic imaging systems and,services to ... before the market opens on Thursday, October 25,2007, financial ... 30, 2007. A conference call is scheduled for ...
... Evaluation of ATIR by Dr. Velardi for ... Mismatched Bone Marrow Transplantation, AMSTERDAM, Netherlands, ... physician initiated European Phase II,clinical study for its lead product ... the successful treatment of,thirteen end stage blood cancer patients with ...
... against identity theft, but what about medical identity theft? ... danger if false entries in medical records lead to ... uses a person,s name and sometimes other parts of ... the person,s knowledge or consent to obtain medical services ...
Other Medicine News:Health News:CRH Medical Corporation opens second clinic in Chicago 2Health News:Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms 2Health News:Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms 3Health News:Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine 2Health News:Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007 2Health News:Kiadis Pharma Announces ATIR Interim Clinical Results 2Health News:Kiadis Pharma Announces ATIR Interim Clinical Results 3Health News:Medical identity theft: the importance of protecting your health records 2
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
Total T3 EIA Thyroid Function 025-BC-1005...
... anti-TPO test kit is a solid phase ... It is designed for the quantitative measurement ... in serum or plasma. The microplate is ... controls and patient samples are pipetted into ...
Medicine Products: